Tag: pharmaceuticals

  • Contract Awarded for Radiation Countermeasure Drug

    Cleveland BioLabs Inc., a drug development company in Buffalo, New York, received a contract from the U.S. Department of Defense (DoD) to develop and stockpile its drug CBLB502 as a medical radiation countermeasure. The initial contract provides $14.8 million for advanced development of the drug, with later options worth $30 million for purchase of doses.…

  • Blood Disorder Gene Therapy Results Published

    The current online issue of the journal Nature features an article with the first results of a clinical trial testing gene therapy on beta-thalassemia, an inherited blood disorder. The trial tests the drug LentiGlobin, developed by bluebird bio (formerly Genetix Pharmaceuticals Inc.) of Cambridge, Massachusetts. The Nature paper describes the experiences of the first patient…

  • Clinical Trial Completed for Psoriasis Antibody

    Biotie Therapies, a drug discovery and development company in Finland, completed a phase 1 clinical trial of its vascular adhesion protein 1 (VAP-1) monoclonal antibody BTT-1023 in patients with plaque psoriasis, the most prevalent type of this disease. Plaque psoriasis affects some 8 in 10 psoriasis sufferers. The clinical trial tested the safety, tolerability, and…

  • Sanofi Aventis to Close Pennsylvania R&D Center

    The Pottstown Mercury reports today that pharmaceutical company Sanofi Aventis, based in France, will close its Great Valley, Pennsylvania research and development site by July 2011. The Mercury says Sanofi Aventis will keep clinical supply and related support activities at the Great Valley site. Elizabeth Baxter, a spokesperson for Sanofi Aventis, told the Mercury that…

  • iPhone App Reports Drug Safety, Adverse Events Info

    Researchers at Children’s Hospital Boston in Massachusetts and University of North Carolina at Chapel Hill have developed MedWatcher, a new iPhone application that tracks the latest drug safety updates and alerts from the Food and Drug Administration (FDA) and the news media. It also lets users report information about drug side effects and view reports…

  • Novo Nordisk to Double China R&D Staff

    Novo Nordisk, a Danish pharmaceutical company, said today it will expand its research and development staff in Beijing, China from 100 to 200 employees by 2015. The additional staff will initially work on new research involving diabetes. The company says its future research scope in China will be broadened to include pharmacological studies other than…

  • Study IDs More Efficient Vaccine Supply Chain Processes

    New research identifies potential processes for drug manufacturers and public health officials to reduce pediatric vaccine supply shortages and still maximize immunity from disease by children. Researchers at University of Illinois at Urbana-Champaign (UIUC) and Rochester Institute of Technology (RIT) in New York have developed a mathematical framework to better understand the implications of the…

  • Industry Report Lists Anti-Infection Drugs in Pipeline

    The Pharmaceutical Research and Manufacturers of America (PhRMA) released today a report listing 395 new drugs designed to fight infections that are nearing the marketplace. Each of the drugs are either in clinical trials or under review by the U.S. Food and Drug Administration. More than one-third of the drugs on the PhRMA list —…

  • European Patent Awarded for Herpes Treatment

    BioAlliance Pharma SA in Paris, France say it has been granted a European patent protecting its product acyclovir Lauriad. This patent, says the company, specifically protects the muco-adhesive tablet containing acyclovir, its process for manufacturing, and its clinical application. According to BioAlliance Pharma, acyclovir Lauriad provides treatment of recurrent herpes labialis with one tablet application…

  • Phase 2 Clinical Trial Planned for Depression Drug

    Rexahn Pharmaceuticals Inc., a clinical stage pharmaceutical company in Rockville, Maryland, submitted today a Phase 2b protocol to the U.S. Food and Drug Administration for the clinical study of Serdaxin, a drug that treats major depressive disorder. The company says Serdaxin may work as an enhancer of serotonin and dopamine in the brain. In Rexahn’s…